Pharmacology

Opioid and cannabinoid receptor signalling Effects of natural variants of opioid receptors on drug action Molecular targets of cannabis constituents Illicit synthetic cannabinoids Opioid receptors in cancer

Redmond W, Cawston E, Grimsey N, Stuart J, Edington A, Glass M, Connor M (2015). Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. Brit J Pharmacol, In Press Cawston E, Connor M, Di Marzo V, Silvestri R, Glass M (2015). Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signalling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. J Med Chem, 58, 5979-5988 Banister S, Moir M, Stuart J, Kevin R, Wood K, Longworth M, Wilkinson S, Beinat C, Buchanan A, Glass M, Connor M, McGregor I, Kassiou M (2015). The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA. ACS Chem Neurosci 6, 1546-1559 Knapman AJ, Santiago M, Connor M (2015). The A6V polymorphism of the human µ-opioid receptor negatively impacts signalling of morphine and endogenous opioids in vitro. Brit of Pharmacol, 172, 2258-2272